BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 29530714)

  • 1. Mesoporous Pravastatin Solid Dispersion Granules Incorporable Into Orally Disintegrating Tablets.
    Song H; Moon C; Lee BJ; Oh E
    J Pharm Sci; 2018 Jul; 107(7):1886-1895. PubMed ID: 29530714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new formulation for orally disintegrating tablets using a suspension spray-coating method.
    Okuda Y; Irisawa Y; Okimoto K; Osawa T; Yamashita S
    Int J Pharm; 2009 Dec; 382(1-2):80-7. PubMed ID: 19686825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pragmatic approach for engineering porous mannitol and mechanistic evaluation of particle performance.
    Al-Khattawi A; Koner J; Rue P; Kirby D; Perrie Y; Rajabi-Siahboomi A; Mohammed AR
    Eur J Pharm Biopharm; 2015 Aug; 94():1-10. PubMed ID: 25960332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Prosolv and Prosolv:Mannitol 200 direct compression fillers on the physicomechanical properties of atorvastatin oral dispersible tablets.
    Gowda V; Pabari RM; Kelly JG; Ramtoola Z
    Pharm Dev Technol; 2015 Jun; 20(4):394-400. PubMed ID: 24397821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coated dextrin microcapsules of amlodipine incorporable into orally disintegrating tablets for geriatric patients.
    Jang DJ; Bae SK; Oh E
    Biomed Pharmacother; 2014 Oct; 68(8):1117-24. PubMed ID: 25458788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further improvement of orally disintegrating tablets using micronized ethylcellulose.
    Okuda Y; Irisawa Y; Okimoto K; Osawa T; Yamashita S
    Int J Pharm; 2012 Feb; 423(2):351-9. PubMed ID: 22138608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a novel direct compressible co-processed excipient and its application for formulation of Mirtazapine orally disintegrating tablets.
    Loke YH; Chew YL; Janakiraman AK; Lee SK; Uddin ABMH; Goh CF; Kee PE; Ng HS; Ming LC; Liew KB
    Drug Dev Ind Pharm; 2024 Jan; 50(1):36-44. PubMed ID: 38149637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Formulation and Evaluation of Baclofen-Meloxicam Orally Disintegrating Tablets (ODTs) Using Co-Processed Excipients and Improvement of ODTs Performance Using Six Sigma Method.
    Abdelmonem R; Abdellatif MM; Al-Samadi IEI; El-Nabarawi MA
    Drug Des Devel Ther; 2021; 15():4383-4402. PubMed ID: 34690500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying.
    Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C
    Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roll compaction of mannitol: compactability study of crystalline and spray-dried grades.
    Wagner CM; Pein M; Breitkreutz J
    Int J Pharm; 2013 Sep; 453(2):416-22. PubMed ID: 23742975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of Texture Analysis Technique in Formulation Development of Lyophilized Orally Disintegrating Tablets Containing Mannitol, Polyvinylpyrrolidone and Amino Acids.
    Hackl E; Ermolina I
    AAPS PharmSciTech; 2019 Jan; 20(2):71. PubMed ID: 30631978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tablet characteristics and pharmacokinetics of orally disintegrating tablets containing coenzyme Q10 granules prepared by different methods.
    Kashiwagura Y; Takusagawa S; Ikematsu Y; Tanaka S; Namiki N; Uchida S
    Acta Pharm; 2023 Mar; 73(1):107-119. PubMed ID: 36692467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spray dried excipient base: a novel technique for the formulation of orally disintegrating tablets.
    Mishra DN; Bindal M; Singh SK; Vijaya Kumar SG
    Chem Pharm Bull (Tokyo); 2006 Jan; 54(1):99-102. PubMed ID: 16394558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The technologies used for developing orally disintegrating tablets: a review.
    Badgujar BP; Mundada AS
    Acta Pharm; 2011 Jun; 61(2):117-39. PubMed ID: 21684842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation, preparation, and evaluation of novel orally disintegrating tablets containing taste-masked naproxen sodium granules and naratriptan hydrochloride.
    Stange U; Führling C; Gieseler H
    J Pharm Sci; 2014 Apr; 103(4):1233-45. PubMed ID: 24532095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Optimization and Evaluation of Orally Disintegrating Tablet of Meloxicam Using Its Menthol Based Solid Dispersions.
    Dehghani H; Taheri A; Homayouni A
    Curr Drug Deliv; 2017; 14(5):709-717. PubMed ID: 27142108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges and emerging solutions in the development of compressed orally disintegrating tablets.
    Al-Khattawi A; Mohammed AR
    Expert Opin Drug Discov; 2014 Oct; 9(10):1109-20. PubMed ID: 25045997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and evaluation of novel multi-channel orally disintegrating tablets.
    Yu J; Shan X; Chen S; Sun X; Song P; Zhao R; Hu L
    Eur J Pharm Sci; 2020 Jan; 142():105108. PubMed ID: 31669391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation of Loratadine Orally Disintegrating Tablets by Semi-solid Extrusion 3D Printing.
    Yi S; Xie J; Chen L; Xu F
    Curr Drug Deliv; 2023; 20(6):818-829. PubMed ID: 36221886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New advances in the characterization of lyophilised orally disintegrating tablets.
    Vanbillemont B; Everaert H; De Beer T
    Int J Pharm; 2020 Apr; 579():119153. PubMed ID: 32084575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.